Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
5,713.00
-49.00 (-0.85%)
Jun 29, 2025, 3:49 PM IDT
-7.59%
Market Cap 65.02B
Revenue (ttm) 61.87B
Net Income (ttm) -4.79B
Shares Out n/a
EPS (ttm) -4.25
PE Ratio n/a
Forward PE 6.48
Dividend n/a
Ex-Dividend Date n/a
Volume 897,292
Average Volume 1,468,244
Open 5,694.00
Previous Close 5,762.00
Day's Range 5,694.00 - 5,740.00
52-Week Range 4,865.00 - 8,431.00
Beta 0.61
RSI 37.93
Earnings Date Jul 30, 2025

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Teva Releases Q2 2025 Aide Memoire

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its ...

3 days ago - GlobeNewsWire

Viatris Eye Drops Data Shows Promise For Blurred Near Vision

Viatris Inc. (NASDAQ: VTRS) and Opus Genetics, Inc. (NASDAQ: IRD) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) fo...

3 days ago - Benzinga

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO , ALVO SDB, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...

3 days ago - Benzinga

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial re...

4 days ago - GlobeNewsWire

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevent...

7 days ago - GlobeNewsWire

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with ...

13 days ago - PRNewsWire

Chaco vs. Teva — we tested the 2 most popular hiking sandals to see how they compare

We compared the Teva Hurricane XLT 2 and the Chaco Z/1 Classic sandals on features like their strap system, footbed, arch design, and color selection.

24 days ago - Business Insider

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Alvotech (NASDAQ: ALVO) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE: RDY) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for gl...

24 days ago - Benzinga

How Do Investors Really Feel About Teva Pharmaceutical Indus?

Teva Pharmaceutical Indus's (NYSE: TEVA) short percent of float has risen 36.14% since its last report. The company recently reported that it has 38.70 million shares sold short , which is 3.39% of a...

24 days ago - Benzinga

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announ...

26 days ago - GlobeNewsWire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announ...

26 days ago - GlobeNewsWire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results fro...

4 weeks ago - GlobeNewsWire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation ...

4 weeks ago - Financial Post

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the present...

4 weeks ago - GlobeNewsWire

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd . (NYSE: TEVA) hosted 2025 Innovation & Strategy Day on Thursday to launch the acceleration phase of its “Pivot to Grow...

4 weeks ago - Benzinga

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acce...

4 weeks ago - GlobeNewsWire

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celi...

4 weeks ago - GlobeNewsWire

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming ...

4 weeks ago - GlobeNewsWire